Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ironwood Pharma ( (IRWD) ) just unveiled an announcement.
On May 8, 2026, Ironwood Pharmaceuticals said Senior Vice President and Chief Financial Officer Gregory Martini will resign effective May 15, 2026, with the company noting his departure is not related to any dispute over its financial reporting. The transition underscores a planned change in Ironwood’s finance leadership while signaling continuity and stability in its accounting practices.
Effective May 15, 2026, Senior Vice President, Corporate Controller and Chief Accounting Officer Ronald Silver will assume the additional roles of interim chief financial officer and principal financial officer, drawing on a tenure at Ironwood that began in 2018 and prior experience at Eze Software Group and RSM. Ironwood emphasized that Silver’s appointment stems from internal succession with no related-party arrangements or transactions, aiming to reassure investors and regulators about governance and independence in its financial oversight.
The most recent analyst rating on (IRWD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
IRWD scores highest on valuation (very low P/E) and a supportive earnings outlook (reiterated 2026 growth/EBITDA targets and deleveraging plans). The main constraint is financial quality, driven by negative equity and earnings volatility, while technicals are moderately supportive but not strongly bullish.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and other specialty conditions. The company operates in the U.S. healthcare and life sciences sector, with a business model centered on advancing innovative prescription treatments and managing a portfolio of marketed and late-stage pipeline assets.
Average Trading Volume: 2,817,390
Technical Sentiment Signal: Hold
Current Market Cap: $673.3M
For detailed information about IRWD stock, go to TipRanks’ Stock Analysis page.